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Circulating tumor cells (CTCs) are prognostic markers for the recurrence of cancer
and may carry molecular information relevant to cancer diagnosis. Dielectrophoresis
(DEP) has been proposed as a molecular marker-independent approach for isolating
CTCs from blood and has been shown to be broadly applicable to different types
of cancers. However, existing batch-mode microfluidic DEP methods have been
unable to process 10 ml clinical blood specimens rapidly enough. To achieve the
required processing rates of 106 nucleated cells/min, we describe a continuous flow
microfluidic processing chamber into which the peripheral blood mononuclear cell
fraction of a clinical specimen is slowly injected, deionized by diffusion, and then
subjected to a balance of DEP, sedimentation and hydrodynamic lift forces. These
forces cause tumor cells to be transported close to the floor of the chamber, while
blood cells are carried about three cell diameters above them. The tumor cells are
isolated by skimming them from the bottom of the chamber while the blood cells
flow to waste. The principles, design, and modeling of the continuous-flow system
are presented. To illustrate operation of the technology, we demonstrate the isolation
of circulating colon tumor cells from clinical specimens and verify the tumor origin
of these cells by molecular analysis. VC 2013 American Institute of Physics.
[http://dx.doi.org/10.1063/1.4774304]
I. INTRODUCTION
Cancer cells shed from a primary tumor may enter the cardiovascular system as circulating
tumor cells (CTCs).1 After invading tissues in distant organs, they may proliferate and form
secondary tumors called metastases. CTCs are typically present in extremely small numbers in
the peripheral blood of cancer patients and their concentration has been shown to be prognostic
of subsequent cancer metastasis.2–4 Currently, only the CellSearch method,5 which depends on
EpCAM cell surface markers, has been approved for clinical use by the FDA for CTC isolation.
However, because EpCAM surface markers are not present in all tumors and may be lost when
cells undergo the epithelial to mesenchymal transition,6 the CellSearch method is not univer-
sally applicable. Dielectrophoresis (DEP),7 a cell surface antigen-independent phenomenon that
depends on cell dielectric properties that reflect cell morphology and membrane surface area,8
has been widely applied for the characterization of cell dielectric properties and for cell manip-
ulation.9,10 Early studies showed that unmodified, viable tumor cells could be separated from
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erythrocytes and peripheral blood mononuclear cells (PBMNs) by DEP,11–13 which has also
been shown to have potential for identifying and isolating prostate tumor initiating cells,14 oral
cancer cells,15,16 melanoma,17 and colorectal cancer cells.18 Most recently, we showed that
DEP is able to discriminate between all of the tumor cell types of the NCI-60 panel and
PBMNs.19 Together, these data suggest that DEP should have wide applicability to isolating
CTCs from blood, regardless of their tissue of origin.
In early experiments, differential trapping of tumor versus normal cells was achieved on
small microelectrode arrays;11,13 however this approach had limited cell discrimination and low
throughput capacity, and dielectrophoretic field-flow-fractionation (DEP-FFF)20–23 was intro-
duced to allow larger batches of cells to be processed and higher discrimination to be attained.
Batch-mode DEP-FFF achieved greater than 90% efficient isolation of cultured breast cancer
cells spiked into PBMNs21 and removed breast tumor cells from CD34þ hemopoietic stem cells
with high efficiency.24
In batch mode DEP-FFF, an aliquot of cells is allowed to settle to the floor at the inlet end
of a separation chamber. Poiseuille flow of eluate is initiated and an AC signal is applied to a
microelectrode array covering the chamber floor. Cells reach equilibrium heights under a balance
of DEP, sedimentation, and hydrodynamic lift forces and are transported through the separation
chamber at rates that reflect the flow velocities at their equilibrium heights.21,25 Cells having dif-
ferent dielectric, density, and mechanical properties are thereby eluted at characteristic times and
separated in time. In order to achieve good cell discrimination, the size of cell batches processed
by a 25 mm 300 mm DEP-FFF chamber was found to be limited to around 106 cells.21 In prac-
tice, CTCs are present at concentrations as low as 1 cell ml1 in the peripheral blood and the
minimum specimen volume considered acceptable for CTC analysis is 7 to 10 ml. A 10 ml clini-
cal blood specimen contains up to 4 107 PBMNs, corresponding to 40 batch-mode DEP-FFF
runs, making that technique impractical for routine clinical applications. In this paper, we describe
a continuous flow DEP-FFF approach for cell isolation that is capable of processing 4 107
PBMNs in less than 1 h, increasing the throughput capacity sufficiently to allow the processing of
clinical specimens for CTC analysis.
II. OVERVIEW OF SEPARATION STRATEGY
To achieve discrimination between different cell types by DEP, cells must be suspended in
a low conductivity medium of physiological osmolarity. This can stress mammalian cells and
elicit changes in their dielectric properties as a result of ionic leakage from the cytoplasm if
they are suspended in the low conductivity medium for more than 103 s.21 This is not a problem
in batch-mode DEP-FFF where the cells may be suspended in the eluate before DEP processing
begins and processing is completed in around 103 s. In continuous flow DEP-FFF, a large speci-
men is processed gradually using a continuous injection approach that takes up to an hour. Sus-
pension of the whole specimen in low conductivity medium prior to starting this slow injection
process is not feasible if the dielectric properties of the cells are to remain unchanged, and cell
discrimination is to remain consistent throughout the run.
To provide for this consistency, we developed the continuous flow DEP-FFF approach
shown in Figure 1. Continuous flow of a low conductivity eluate of physiological osmolarity is
provided from an inlet port (a) to an outlet port (f), establishing a Poisseuille flow profile in a
separation channel of 200 mm length, 25 mm width, and 314 lm height. In the specimen injec-
tion zone (b), the specimen, comprising a cell suspension in physiological medium, is fed
through a slot in the bottom of the chamber at a continuous flow rate qin, which is much lower
than the eluate inlet flow rate Qin. As a result of the relative flow rates, the specimen forms a
thin lamina flowing adjacent to the floor of the chamber beneath the main eluate flow stream.
As the thin specimen lamina travels along the chamber floor in the ion-diffusion region, cells
find themselves subjected to sedimentation and weak hydrodynamic lift forces and settle to
equilibrium heights very close to the chamber floor (see Figure 1(c)). Meanwhile, ions diffuse
from the thin specimen lamina into the main eluate flow stream, while non-ionic osmolytes
counter-diffuse from the eluate into the specimen lamina. As a result, the high conductivity of
011807-2 Shim et al. Biomicrofluidics 7, 011807 (2013)
 Reuse of AIP Publishing content is subject to the terms at: https://publishing.aip.org/authors/rights-and-permissions. Downloaded to  IP:  128.83.205.78 On: Tue, 08 Mar
2016 21:05:11
the specimen lamina is reduced, while the osmolarity near the cells is maintained at a physio-
logical level. After flowing a sufficient distance Lmix along the chamber for diffusion to reach
equilibrium (see Sec. IV), the ion concentration, and resultant electrical conductivity of the me-
dium, becomes independent of height in the chamber and small enough for DEP separation to
be undertaken. The flow then enters the DEP separation region, where microelectrodes on the
chamber floor are energized by an appropriate AC voltage to impose DEP forces on the cells.
As they flow over the microelectrodes, tumor cells are pulled towards the chamber floor by pos-
itive DEP forces, while PBMNs are repelled and levitated by negative DEP forces. Cells even-
tually move to heights at which the DEP, sedimentation, and hydrodynamic lift forces balance
(see Figure 1(d)). Finally, as the flow enters the tumor cell skimming zone (e), fluid is with-
drawn through a slot in the chamber floor at a rate qout, skimming off a thin lamina of fluid
from the bottom of the chamber up to a height hs. Tumor cells, which have reached equilibrium
heights close to the chamber floor, are thereby captured through the withdrawal slot while
PBMNs, which reached equilibrium heights above the skim height hs, are carried over the slot
and exit to waste with the main eluate exit flow Qout at (f). The detailed design and operation
of these stages will be described in the following sections.
III. CONTINUOUS INJECTION AND SKIMMING
As indicated, the aim in continuous flow DEP-FFF is to transport the specimen along the
floor of the separation chamber in a thin lamina that flows beneath the main eluate stream. For
the parabolic Poiseuille flow velocity profile, the thickness of this specimen lamina, hin, above
the chamber floor is related to the injection flow rate, qin, and the eluate inlet rate Qin according
to the expression Qin=ðQin þ qinÞ ¼ 3ðhin=HÞ2  2ðhin=HÞ3, where H is the height of the cham-
ber. For a very thin specimen lamina, qinQin and hin  Hðqin=3QinÞ1=2. Similarly at the with-
drawal port, a thin lamina of fluid may be skimmed from the chamber floor up to a height hs
by withdrawing fluid at a rate qout, where hs  Hðqout=3QoutÞ1=2.
FIG. 1. DEP-FFF isolation of tumor cells from PBMNs in a continuous-flow chamber viewed from the side. The principles
of specimen injection, cell settling and specimen deionization, height equilibration by force balance, and isolation of the
tumor cells from PBMNs by skimming are described in the text. The relative vertical scale of the extremely thin chamber is
exaggerated by 120-fold for clarity.
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In practice, qin and qout are very small and cell sedimentation can result in imperfect injection
and skimming behavior if there are either vortices or positions of low flow rate at the injection or
withdrawal slots. In order to optimize the slot design, we simulated flow profiles for various
chamber heights, slot widths, and flow rates using COMSOL MULTIPHYSICS software (Stockholm,
Sweden) assuming that the fluid was incompressible and had a density of 1036 kg m3 and a
dynamic viscosity of 1.31 103 Pa s, reflecting the properties of the eluate medium used for our
cell isolation experiments. The results for the withdrawal slot simulations are shown in Figure 2.
The behavior at the inlet slot region is a mirror image of that at the withdrawal slot.
Desirable skimming behavior was observed when the slot width dout was small compared
with the chamber height H (Figure 2(a)). In this case, a well defined separation region at the
slot opening cleanly split the thin lamina of height hs at the chamber bottom from the main
chamber flow. Streamlines above the skim height hs travelled essentially horizontally across the
slot, and no regions of low flow rate or significant vortices were generated in the separation
region. In this case, tumor cells close to the chamber floor would be skimmed cleanly into the
withdrawal slot, while PBMNs in the fluid above the skim height would be rapidly carried over
the slot without being thrown into the slot by inertial forces or having the opportunity to sedi-
ment into the slot from regions of low flow rate.
As the withdrawal slot width dout was increased, the separation behavior became less ideal
(Figure 2(b)). Although the skim height hs still followed the Poiseuille model (equations above),
the flow in the slot opening became more complex. Streamlines above the skim height hs trav-
elled downwards into the mouth of the slot causing a depression by a distance ds of the region
where the withdrawal and main chamber flow streams split. Furthermore, a vortex of diameter
Wv formed in the withdrawal tube and significant regions of low flow rate were generated in
the separation region. In this case, tumor cells close to the chamber floor would be skimmed
FIG. 2. COMSOL MULTIPHYSICS simulations of the fluid flow behavior at the DEP-FFF chamber withdrawal slot for different
geometries and flow rates. (a) When the withdrawal slot width dout is small compared with the chamber height H, optimum
skimming behavior is observed with negligible vortices or regions of low flow rate; (b) as the relative withdrawal slot width
is increased, a vortex forms within the slot, streamlines from the main channel are depressed into the slot region and zones
of low flow rate appear; (c) the skimming height hs accurately follows that predicted by simple Poiseuille flow theory
(see text). Vorticity (d) and depression of the streamlines from the main channel (e) increase with increasing slot width.
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into the withdrawal slot but then potentially recirculated in the vortex. Because of the curvature
of the streamlines, some may be thrown by inertial forces into the depressed streamlines of the
main chamber flow, carried back into the main chamber, and lost to waste. Meanwhile, PBMNs
traveling above the skim height that followed the depressed streamlines from the main channel
into the chamber mouth would not only have a tendency to be thrown into the withdrawal flow
by the curvature of the streamlines but also would need to be carried uphill from their
depressed locations well down inside the mouth of the withdrawal slot back into the main
chamber against the sedimentation forces acting on them. As a result of these effects, some
PBMNs would enter the withdrawal stream and contaminate the tumor cell fraction.
Our simulations establish criteria for designing efficient withdrawal slots and show, in par-
ticular, that a withdrawal slot of width dout<H/3, regardless of the flow rate, exhibits negligible
depression of the main chamber streamlines into the mouth of the withdrawal port (Figure 2(e))
as well as low vorticity (Figure 2(d)). Similar principles apply to the injection slot design to
prevent the potential for cell accumulation in the mouth of the injection slot. In our experi-
ments, a chamber height of 314 lm and injection and withdrawal slot widths of 127 lm were
chosen, corresponding to the flow conditions shown in Figure 2(a). At the inlet, the specimen
was injected at a rate of qin¼ 25 lk min1 with a main eluate flow rate Qin¼ 1000 ll min1,
leading to a specimen lamina thickness hin¼ 29.3 lm at the inlet. At the outlet, the withdrawal
rate was qout¼ 20 lk min1 leading to a skimming height of hs¼ 26.4 lm. In our experiments,
the injection and withdrawal flows were provided by 1 ml syringes driven by digital syringe
pumps (KDS210, KD Scientific, Holliston, Massachusetts) and the eluate flow by a gear pump
(Ismatec, Glattbrugg, Switzerland).
The concept of combining and splitting lamina flow streams in a microfluidic channel is
the basis of the so-called H filter design in which two inlet ports enter from opposite sides at
one end of the chamber to combine lamina flows and two withdrawal ports exit from opposite
sides at the other end of the chamber to split lamina flows. In cell separation applications, sedi-
mentation of cells is a significant problem at low flow rates and the channels and tubing that
carry the cells into and out of the separation chamber should be oriented vertically to avoid cell
loss resulting from settling and adherence to tubing surfaces. In the H-filter design,26 regions of
stagnant flow can occur at both ends of the chamber at the interfaces of the flow streams. At
the low flow velocities required for isolation of tumor cells, sedimentation of PBMNs would
occur in the slow-moving region of fluid heading towards the top withdrawal port in the
H-filter configuration, and some PBMNs would inevitably fall into the lower withdrawal port
and contaminate the tumor cell isolate. In the p configuration of our continuous flow DEP-FFF
chamber described here, the possibility of contamination is greatly reduced because stagnant
flow is eliminated from the fluid interface regions. Tumor cells flow directly downward through
the withdrawal slot in the chamber floor while PBMNs travel horizontally. Furthermore, micro-
electrodes are positioned on the chamber floor on both the upstream the downstream sides of
the withdrawal slot in our design. These continue to levitate PBMNs by DEP forces in the slot
region and on the far side of the slot. This helps reduce still further the likelihood PBMNs will
fall into the withdrawal slot and contaminate the tumor cell isolate. In these ways, our p config-
uration improves significantly upon the H-filter design concept for applications involving sedi-
mentary particles such as cells.
IV. DEIONIZATION
In order to pull tumor cells towards the microelectrodes on the floor of our separation cham-
ber by positive DEP while simultaneously repelling PBMNs high into the eluate flow stream by
negative DEP, as required in our cell isolation strategy, the cell suspending medium conductivity
must be much lower than the cell cytoplasmic conductivity.9 The starting conductivity of our
specimens was 1.4 S m1, approximately the same as that of the cell cytoplasms, and this needed
to be lowered to a target value of about 60 mS m1 before the cells could be subjected to DEP
separation. The reduction in conductivity was accomplished by using diffusion to deplete the ions
in the specimen as it moved through the cell settling and ion diffusion zone shown in Figure 1(c).
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The length of the ion diffusion zone was chosen in accordance with the chamber height H and
flow rate Qin to insure that ions had sufficient time to diffuse throughout the chamber height
before the sample entered the DEP zone. The required mixing length Lmix for a diffusible species
has been analyzed for the H-filter microfluidic configuration27 and, by analogy for our p configura-
tion device, may be written as Lmix  HðQin þ qinÞ=ðWDÞ, where W is the width of the chamber
in the direction perpendicular to the plane of Figure 1 and D is the diffusion coefficient of the dif-
fusing species.
Our cell specimens contained between 20 106 and 40 106 PBMNs (containing trace levels
of tumor cells) collected from whole blood by centrifugation over Histopaque 1077 (Cat
10771-100 ml, Sigma-Aldrich, St Louis, USA) and were suspended in 1 ml RPMI medium that
had been adjusted to a density of 1036 kg m3 by adding iodixanol (OptiprepTM Density Medium
D1556, Sigma-Aldrich, St Louis) to a concentration of 11%.21 We used the eluate recipe devel-
oped in our earlier DEP-FFF studies21,28 composed of an aqueous solution of 9.5% sucrose
(S7903, Sigma-Aldrich, St Louis, MO), 0.1 mg ml1 dextrose (S73418-1, Fisher, Fair Lawn, NJ),
0.1% pluronic F68 (P1300, Sigma-Aldrich, St Louis, MO), 0.1% bovine serum albumin (A7906,
Sigma-Aldrich, St Louis, MO), 1 mM phosphate buffer pH 7.0, 0.1 mM CaAcetate, 0.5 mM
MgAcetate, and 100 units ml1 catalase (C30, Sigma-Aldrich, St Louis, MO). This mixture was
adjusted to a conductivity of 30 mS m1 with KCl. Pluronic F-68 provided mechanical stabiliza-
tion of cell membranes under flow conditions,29 catalase protected cells from reactive oxygen
intermediates,30 and bovine serum albumin inhibited cell adhesion to tubing and chamber surfa-
ces. The specimen and eluate densities were both 1036 kg m3, as a result of their iodixanol and
sucrose contents, respectively, and this parity of densities was chosen to avoid the possibility of
convection mixing when the flow streams were combined in the continuous flow chamber. After
injection into the chamber, the Naþ, Kþ, and Cl ions that dominated the high conductivity of
the specimen diffused throughout the eluate. Sucrose counter diffused from the eluate to maintain
the osmolarity of the cells at a physiological level so they were not osmotically stressed, which
would have impacted cell size and membrane dielectric characteristics.28
We simulated the diffusion of ions and sucrose in our continuous flow device using the
COMSOL MULTIPHYSICS software and the results for the conductivity distributions in key zones of the
chamber are shown in Figure 3. In the specimen injection zone (Figure 3(a)), a very large con-
ductivity gradient exists where the specimen stream (1400 mS m1) first joins the main eluate
flow (30 mS m1). At a distance 18 mm downstream from the specimen inlet, in the cell settling
and ion diffusion zone (Figure 3(b)), the ion conductivity is clearly spreading upwards through
the chamber and by the time the flow reaches the DEP equilibration zone 40 mm downstream
from the specimen inlet and the tumor cell skimming zone 80 mm downstream from the specimen
inlet (Figure 3(c)), ion diffusion is essentially complete and the conductivity is homogeneous
throughout the chamber height at about 61.5 mS m1. Sucrose diffusion is also completed before
the specimen reaches the DEP equilibration zone.
FIG. 3. COMSOL-MULTIPHYSICS simulations of the conductivity distribution in the flow stream (a) at the specimen injection
zone, (b) at the midpoint of the cell settling and ion diffusion zone, and (c) at the cell skimming zone.
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To verify these simulation results, we measured the AC current drawn by the microelec-
trode array. This current depends much more sensitively on the conductivity immediately adja-
cent to the microelectrode that on the conductivity high in the chamber. We found that the
microelectrode current was the same under continuous specimen injection conditions as when
the chamber was filled with a homogeneous medium having a conductivity of 61.5 mS m1.
This showed that the ion concentration at the microelectrode plane was the same in both cases,
proving that diffusion was complete. Furthermore, we conducted an experiment in which fluid
leaving the ion diffusion region was skimmed from the chamber floor up to different heights by
altering the withdrawal flow rate. The conductivity of the withdrawn fluid was 61.5 mS m1
regardless of the skim height, also showing that diffusion was complete.
This method of reducing the conductivity during flow through the ion diffusion zone
insured that all cells were subjected to exposure to low conductivity conditions for the same,
relatively short, period of time regardless of when they entered the chamber during the 40 min
specimen processing time. Passage of cells through this zone took about 180 s and this afforded
sufficient time for cells to sediment to equilibrium positions close to the chamber floor so that
they entered the DEP equilibration zone at identical heights and all were subjected to similar
electric field conditions.
V. DEP STAGE
The frequency and magnitude of the electrical signal applied to the microelectrodes in
the DEP equilibration zone (Figure 1(d)) are chosen so that the tumor cells are pulled towards
the chamber floor while the PBMNs are repelled high above it. This is possible because the
direction of the DEP force is determined by whether the applied electric field frequency is
greater or less than the characteristic “crossover frequency” fco of a given cell type.
10,31,32 In
the accompanying article,19 we show that the crossover frequencies of all cell types derived
from solid tumors in the widely representative NCI-60 panel of cancers lie far below those of
all the subpopulations of peripheral blood cells. By choosing a signal frequency that is in
between the crossover frequencies of tumor cells and PBMNs, it is possible to impose the
desired differential DEP forces that drive cell separation and allow tumor cells to be isolated
by skimming them from the chamber floor. At the equilibrium eluate target conductivity of
60 mS m1 used for our continuous flow DEP-FFF tumor cell isolation experiments, the cross-
over frequencies fco of all solid tumor cell types were well below 100 kHz while those of all
the blood cell subpopulations were above 200 kHz. Therefore, a DEP signal frequency of
130 kHz was chosen for our tumor cell isolation experiments. (Note that the crossover fre-
quency is proportional to the cell medium suspension conductivity, so that the fco values
measured by batch mode DEP-FFF at 30 mS m1 in the accompanying article19 are half the
corresponding fco values at the 60 mS m
1 target conductivity value used for continuous mode
isolations in this article.)
The DEP force imposed on cells depends on the square of the applied voltage V, suggest-
ing it might be advantageous to use a high DEP voltage to increase the height differential
between tumor and PBMNs leaving the DEP equilibration zone.19 However, the electric field
that gives rise to the DEP force also induces a transmembrane potential difference that can
stress cells and cause them to become leaky towards ions and/or electroporated, which could
alter their DEP properties and confound their separation characteristics. The magnitude of the
induced transmembrane potential difference depends upon the electric field strength, the cell
diameter, and the applied electric field frequency.30 Because of their larger diameter and closer
proximity to the microelectrodes during continuous DEP-FFF isolation, tumor cells are more
prone than PBMNs to damage by a high voltage in our DEP-FFF cell isolation experiments.
However, we found that we could use an applied voltage of 4 V p-p in our experiments to pro-
vide strong DEP forces without evidence of diminished tumor cell isolation efficiency. Catalase
was included in our eluate buffer as in our previous work21,28 to protect the cells from a low
concentration of reactive oxygen intermediates that may be produced by electrochemical proc-
esses at the microelectrodes.30
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To confirm the differential height distributions of tumor cells and PBMNs under force bal-
ance conditions, we ran a batch-mode DEP-FFF experiment using the chamber described in ear-
lier work28,33 and recorded the time-dependent elution profile of a mixture of PBMNs from
healthy donors and MDA-MB-231 human breast cancer cells for a DEP frequency that corre-
sponded to our continuous flow separation conditions.19 The cell elution profile was determined
using a laser particle counter (PC2400D, ChemTrac Systems, Norcross, Georgia, USA) to count
and size the cells as they left the batch-mode chamber. Because the cells were carried through
the chamber at the velocities of the eluate at their equilibrium heights, the cell elution times
could be mapped directly to the cell equilibrium height distribution in the chamber. The results
are shown in Figure 4 and it may be seen that the MDA-MB-231 cells traveled through the
DEP-FFF chamber between 5 and 13 lm above the chamber floor, while the PBMNs were
transported at between 14 and>40 lm height. Tumor cells may be isolated from PBMNs in
continuous flow DEP-FFF by using a skim height that is between the tumor cell and PBMNs
transport heights under the prevailing DEP field conditions.
In Figure 4, the batch mode DEP-FFF chamber had a microelectrode array area of 7500 mm2
and the power output capacity of our signal generator limited the maximum DEP voltage to 2.8 V
p-p. For continuous flow DEP-FFF, our chamber had a microelectrode array area only one third that
size, which permitted us to use the higher operating voltage of 4 V p-p. The DEP-FFF force balance
equation19,28,34 showed that the levitation height for PBMNs under those conditions was >27 lm.
Accordingly, we chose a skimming height of hs¼ 26 lm by setting the withdrawal rate to
qout¼ 20 ll min1 for continuous flow DEP-FFF cell isolation experiments (as in Figure 2(a)).
In principle, fluid convection cells could form adjacent to energized DEP electrodes as the
result of temperature gradients associated with Joule heating of the fluid. Convection cells on
our periodic DEP microelectrode array would be expected to have the same spatial periodicity
as the DEP force field and it might be possible for convection and DEP fields to act in
FIG. 4. Height distributions of MDA-MB-231 human breast cancer cells and PBMNs as they flowed through the chamber
in force-balance equilibrium during batch mode DEP-FFF separation. The height distribution was mapped from the cell
elution times assuming that the transit velocities of the cells reflected their heights in the Poiseuille hydrodynamic flow pro-
file inside the DEP-FFF chamber.
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combination to alter the height at which cells are transported over the microelectrode array and
thereby impact the cell isolation characteristics. This possibility was neglected in the analytical
equations we used to describe DEP-FFF and the effect, if present, seems to be relatively small
because one result of it would be to shift the apparent crossover frequency at which the direc-
tion of the DEP force on cells appears to reverse in DEP-FFF. In this case, the crossover fre-
quency deduced from DEP-FFF would differ from the true crossover frequency measured by
conventional DEP methods. Even though we did not observe such a frequency shift, we believe
that this phenomenon is worthy of more careful study in which the modeling work is extended
to include coupling of thermal, hydrodynamic and electrokinetic parameters in determining the
fluid flow and cell transit behaviors. Future modeling including such coupling could potentiate
further improvements to continuous mode DEP-FFF.
VI. TESTS WITH CLINICAL SPECIMENS
We ran tests of continuous flow DEP-FFF isolation of MDA-MB-435, MDA-MB-231, and
other cultured tumor cells spiked into PBMNs from healthy donors to compare with our earlier
batch-mode DEP-FFF experiments.21 Measurements were conducted using a DEP-FFF chamber
160 mm long having a width of 25 mm, a height of 314 lm, and an inlet to outlet slot spacing
of 90 mm. The chamber floor was lined by a microelectrode array based on the design detailed
earlier33 in which parallel gold-on-copper microelectrodes of 50 lm width and spacing were
patterned on a kaptan substrate. However, only the last 45 mm of the microelectrode array lead-
ing up to the outlet slot was energized. The DEP and flow conditions were as described in ear-
lier sections, namely 2000 ll min1 and 20 ll min1 for eluate and injection/withdrawal rates,
respectively, a DEP signal of 130 kHz at 4 V p-p, and a conductivity of the emerging eluate of
about 64 mS m1.
Cultured tumor cells were prelabeled with fluorescent dye (CellTracker Green CMFDA,
Life Technologies, Grand Island, New York) and spiked into PBMNs from 10 ml blood speci-
mens at concentrations ranging from 50 to 600 per ml blood. Using the method, we developed
earlier for characterizing batch-mode DEP-FFF separations,24 the output port of the DEP-FFF
chamber was connected to a modified FACS instrument and the labeled tumor cells were gated
and counted by their fluorescence (Ex 488 nm, Em 517 nm) as they emerged. These measure-
ments confirmed that, independently of spiking density, tumor cell isolation efficiencies of
70%–80% were achieved. Figure 5 shows scatter plots obtained for MDA-MB-435 cells at three
different spiking concentrations. The average collection efficiency was found to be 75% and in-
dependent of spiking density.
Despite these encouraging results using spiked samples, we were made aware that the dielec-
tric properties of the blood of cancer patients might be modified by their disease and treatment
regimen. For example, leukocytosis, thrombocytosis, and increased acute phase protein levels in
the blood are typically part of a chronic systemic inflammatory response to late stage malig-
nancy.35 These factors have the potential to lead to anomalous blood cell subpopulations that
FIG. 5. Flow cytometric (FACS) scattergrams showing the recovery of tumor cells from PBMNs spiked with (a) 6000,
(b) 2000, and (c) 500 MDA-MB-435 cultured cells prelabeled with CellTracker Green fluorescent dye.
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might contaminate CTCs during DEP-FFF isolation. Therefore, we conducted a preliminary trial
using a limited number of clinical specimens from late stage cancer patients to establish whether
CTCs could be isolated from blood under realistic clinical conditions. Peripheral blood specimens
were obtained as part of the initiative for molecular profiling in advanced cancer therapy
(IMPACT) Trial at The University of Texas M.D. Anderson Cancer Center with informed patient
consent and the approval of Institutional Biosafety Committee. Specimens of at least 7 ml volume
were collected from patients in 10 ml BD purple cap (EDTA) vacutainers and processed within
3 h. The PBMNs, putatively containing CTCs, were separated from the patient specimens over
Histopaque 1077 and subjected to continuous DEP-FFF also using the experimental conditions
described in Secs. III–V above. The isolate from the withdrawal slot was collected in a 1 ml sy-
ringe for each specimen over the approximately 40 min processing time.
The FACS approach is not feasible for analyzing CTCs isolated from clinical specimens
because a 10 ml blood specimen may contain as few as ten CTCs and very rarely more than
hundreds and downstream immunostaining in cell suspension (as opposed to fluorescent dye
preloading used to prepare cells before spiking experiments) followed by subsequent FACS
analysis are too lossy to use to count such small cell populations accurately. Therefore, a
CytoproTM instrument (Wescor Model 7620, Logan, Utah) was used to mount the cells from
this isolate onto two microscope slides. One slide was immunostained for cytokeratin using
FITC-conjugated CK3-6H5 antibodies (Miltenyi Biotec, Bergisch Gladbach, Germany) com-
bined with nuclear staining by DAPI (D1306 Molecular Probes, Eugene, Oregon). An example
is shown in Figure 5, where putative CTCs show green fluorescence due to the presence of
cytokeratin and both CTC and PBMN nuclei exhibit blue fluorescence.
The primary tumors of all patients enrolled in the IMPACT trial are subjected to screening
for somatic mutations associated with their primary cancers. In order to verify the presence of
CTCs in our isolates, the unstained slide was subjected to molecular analysis. DNA was
extracted from the slide using PicoPure (cat 11815-00, Applied Biosystems) then further
cleaned with a QIAamp DNA Micro Kit (cat 56304, Qiagen). The DNA was preamplified using
the following primers: Forward: ATGACTGAATATAAACTTGTGGTAGTTGGA, Reverse:
GAATTAGCTGTATCGTCAAGGCACT, Vic Reporter: CTTGCCTACGCCACCAG, FAM
Reporter: CTTGCCTACGTCACCAG. The Taqman Pre-Amp Master Mix (Cat 4391128) was
employed according to the protocol specified by Fluidigm. The sample from the slide, together
with a positive and a negative control were tested using a Fluidigm 48.48 Genotyping Array
(cat BMK-M-48.48GT, Fluidigm) according to Fluidigm’s protocol. For the colon cancer
specimen shown in Figure 6, the somatic mutation in the primary tumor was KRAS G13D.
MDA-MB-231 was used as a positive control because it possesses this mutation. The specimen
exhibited a positive result with a signal intensity that indicated approximately 10% of the cells
on the slide had the KRAS G13D mutation, mirroring the proportion of cells that stained posi-
tively for cytokeratin in Figure 6. This not only verified that sufficient CTCs were present on
the slide to identify the cancer-causing gene but also shows that the continuous flow DEP-FFF
method coupled with molecular analysis may be suitable for clinical screening purposes. A sig-
nificant advantage of this DEP-FFF CTC isolation approach is that it is label-free and that the
isolated CTCs are viable and unmodified. Therefore, these cells are also suitable for a wide
range of alternative molecular investigational techniques including gene expression analysis.
VII. DISCUSSION
Dielectrophoresis is capable of discriminating between blood and tumor cells on the basis
of cell size and membrane morphology that contribute to differences in cell membrane area and
consequently to cell dielectric properties.8 This separation criterion is independent of cell
surface protein markers and suggests that DEP provides an approach to isolating CTCs that is
applicable to a broad range of cancers. In the accompanying article, we confirm this wide
potential applicability by showing that the dielectric properties of all solid tumor cell types in
the NCI 60 panel of cancer cell lines, regardless of their tissue of origin, exhibit dielectric prop-
erties that are greatly different from those of PBMNs and should allow their isolation from
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blood.19 We showed previously that tumor cells may be isolated from the PBMNs of normal
donors by batch mode DEP-FFF but that method was capable of handling< 5% of the desired
specimen size for clinical analysis of CTCs.21 Here, for the first time, we have detailed all the
operational stages of a continuous flow DEP-FFF system that is capable of processing 10 ml
clinical specimens in less than 1 h. We have confirmed that this method is capable of not only
efficiently isolating cultured cells from PBMNs of healthy donors but also CTCs from clinical
specimens derived from cancer patients. Some of the underlying technology presented here has
been licensed to ApoCell Inc, which is developing a commercial instrument based on our
design concepts.36
Our results indicate that continuous flow DEP-FFF may have important applications for
clinical CTC analysis. Additional studies need to be undertaken to demonstrate that this new
method is as widely applicable as our data suggest and to compare it to competing approaches.
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